Organon & Co. (NYSE:OGN) Q1 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon First Quarter 2023 Earnings Conference Call.
Stay updated with breaking news from Established Brands. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon First Quarter 2023 Earnings Conference Call.
First quarter 2023 revenue of $1,538 millionFirst quarter 2023 diluted earnings per share of $0.69 and non-GAAP Adjusted diluted earnings per share of $1.08Both reported and non-GAAP Adjusted diluted earnings per share include a negative impact of $0.03 per share for acquired in-process research and development (IPR...
Organon (OGN) stock fell ~10% on Thursday after Q1 results. Read more here
The healthcare industry outlook is currently uncertain due to a combination of factors such as economic troubles, a shortage of healthcare workers, and the ongoing COVID-19 pandemic.
The announcement comes after Carlyle announced a strategic partnership with VLCC through the acquisition of majority stake in the company in December 2022.